Investigating a genetic disorder linked to KCa2.3 channels and its effects
Official title: Channelopathy of KCa2.3 and Zimmermann-Laband syndrome
Funded at Chapman University · NIH-10872793 · Data updated 2026-11-12
This study is looking at a rare condition called Zimmermann-Laband syndrome 3 (ZLS3) to understand how certain gene changes affect how cells use calcium, which is important for their health, and the findings could help develop new treatments for people with this condition.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Chapman University NIH-funded |
| Lab location | 1 site (Orange, United States) |
| Project start | April 1, 2024 |
| Project end | March 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $434,024 |
| NIH project number | 1R15NS130420-01A1 |
| Project ID | NIH-10872793 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Zimmermann-Laband syndrome or those exhibiting related genetic mutations.
✕Less likely to help
Patients without genetic mutations linked to KCa2.3 channels or those with unrelated developmental disorders may not benefit from this research.
What this research studies
This research focuses on Zimmermann-Laband syndrome 3 (ZLS3), a rare genetic disorder that leads to developmental delays and physical abnormalities. The study aims to understand how specific mutations in the KCa2.3 channels affect calcium sensitivity, which is crucial for normal cellular function. By exploring the mechanisms behind these mutations, the researchers hope to identify potential therapeutic targets. Patients with ZLS3 may benefit from insights gained through this research, which could pave the way for future treatments.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients with Zimmermann-Laband syndrome.
How similar studies have gone: While research on KCa2.3 channels has been conducted, the specific focus on ZLS3 mutations represents a novel approach.
Where this research is happening
-
Chapman University
Orange, United States Active
Researchers
- Principal investigator: Zhang, Miao — Chapman University
- Study coordinator: Zhang, Miao
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.